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Abstract: Antiplatelet therapy plays a fundamental role in reducing atherothrombotic events 
by several pathways. The present work reviews available evidence on antiplatelet therapy both 
for primary prevention and in the presence of established peripheral, cerebral, or cardiac isch-
emic disease. Due to the importance of adherence to therapy to   achieve optimal effects, special 
attention is given to the use of fixed-dose oral formulations in the clinical subset of patients in 
whom double antiplatelet therapy has proven indications.
Keywords: aspirin, clopidogrel, ticlopidine, fixed-dose combinations
Introduction
Interaction between platelets and the endothelium, whilst a valuable mechanism 
under normal conditions to stop bleeding from a wound, is involved in the majority 
of morbidity and mortality events occurring in Western countries.1–3
In fact platelets, an enucleated bone marrow product, ensure vascular integrity by 
differencing lesions from normal endothelium. This ability depends on contact of the 
platelet with several extracellular matrix constituents, including von Willebrand factor, 
proteoglycans, collagen type IV , nidogen, laminin, and fibulin.3,4
In this context, adenosine diphosphate (ADP) is an important platelet activator, 
inducing A2 thromboxane synthesis (Figure 1). For example, clopidogrel reduces 
platelet aggregation by irreversible binding inactivation of ADP receptors (P2Y12), 
a requisite for glycoprotein IIb/IIIa receptor activation, whereas aspirin (ASA) 
inhibits thromboxane A2 production with consequent glycoprotein IIb/IIIa receptor 
inactivation.6–8
Considering the striking role of platelet and endothelial interaction in the 
  pathogenesis of atherothrombotic events, the possibility of reversible or irreversible 
modulation of platelet activation represents one of most imperative contemporary medi-
cal   challenges.9 The present work reviews available evidence for antiplatelet therapy 
both in primary and secondary prevention. Due to the importance of adherence to 
therapy for achieving the desired effects, special attention is paid to the use of fixed-
dose oral formulations in the clinical subset of patients in whom double antiplatelet 
therapy has proven indications.
Primary prevention
Single antiplatelet therapy in primary prevention is widely debated.11–13 Several   studies 
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prevalence, diabetes mellitus status, and baseline medication 
use (eg, statin treatment). For these reasons, clear evidence 
is lacking in high-risk populations. The major clinical trials 
testing the effects of single antiplatelet therapy in primary 
prevention are listed in Table 1.
A randomized clinical trial by Sacco et al tested the effect of 
ASA 100 mg/day plus vitamin E 300 mg/day on the   composite 
endpoint of cardiovascular death, stroke, or   myocardial infarc-
tion in patients with at least one   cardiovascular risk factor 
(n = 4495). After a median   follow up of 3.7 years, ASA 
treatment was associated with a   nonsignificant reduction in 
the main endpoint (relative risk [RR] 0.90; 95% confidence 
interval [CI]: 0.50–1.62) in diabetic patients, accompanied by 
a similarly nonsignificant increase in   cardiovascular deaths 
(RR 1.23; 95% CI: 0.69–2.19). However, in nondiabetic 
patients with at least one other cardiovascular risk factor, total 
cardiovascular events were significantly reduced (RR 0.59; 
95% CI: 0.37– 0.94).14
In another randomized trial, Ridker et al assigned nearly 
40,000 healthy women to receive ASA 100 mg or placebo 
and compared outcomes (nonfatal myocardial infarction, 
nonfatal stroke, or death from cardiovascular causes) at 
10-year follow-up. At the end of the study, the risk of stroke 
was reduced by 17% in the ASA versus the placebo group 
(RR 0.83; 95% CI: 0.69–0.99). While the risk of ischemic 
stroke was reduced by 24% (RR 0.76; 95% CI: 0.63–0.93), 
the increase in hemorrhagic risk was not significant (RR 1.24; 
95% CI: 0.82–1.87). Fatal or nonfatal myocardial infarction 
was not affected by ASA use (RR 1.02; 95% CI: 0.84–1.25), 
as cardiovascular death (RR 0.95; 95% CI: 0.74–1.22). Of note 
Table 1 Major clinical trials testing the effects of single antiplatelet therapy in primary prevention
Aspirin dose (mg) Endpoint Conclusions
Baigent et al11 50–500 CV and hemorrhagic events No ASA benefits versus placebo
wolff et al12 75–500 CV and hemorrhagic events Risk reduction for Mi in men and stroke in women, 
increased serious bleeding risk
Sacco et al14 100 CV death, stroke, Mi No benefit in diabetics, slight advantage in diabetes  
plus one risk factor
Ridker et al15 50 CV death, stroke, Mi No significant advantage
Berger et al17 75–500 CV and hemorrhagic events No ASA benefits versus placebo
De Berardis et al18 75–325 CV death, stroke, Mi MI reduction in men, no survival benefit
Younis et al19 75–325 CV and hemorrhagic events No ASA benefits versus placebo
Abbreviations: CV, cardiovascular; ASA, aspirin; Mi, myocardial infarction.
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is that   gastrointestinal bleeding was more frequent in the ASA 
arm (RR 1.40; 95% CI: 1.07–1.83). The authors of this trial 
concluded that ASA treatment seemed to lead to superior 
outcomes compared with placebo only in women aged over 
65 years.15
Fowkes et al selected patients at increased risk, w  ithout 
previous cardiovascular events, by an   atherosclerosis i  ndicator, 
ie, impaired ankle brachial index.16 Over 3000 patients were 
enrolled and were randomized to receive ASA 100 mg daily 
or placebo. The primary endpoint was a composite of fatal 
or nonfatal coronary events, stroke, or revascularization. 
The secondary endpoint was all-cause   mortality. After the 
eight-year follow-up, no difference emerged concerning the 
primary endpoint (RR 1.03; 95% CI: 0.84–1.27). Also, for 
all-cause mortality, the study groups achieved similar results 
(RR 0.95; 95% CI: 0.77–1.16). However, the risk of major 
hemorrhage was significantly increased in the ASA group 
(RR 1.71; 95% CI: 0.99–2.97).
Due to the equivocal results of the aforementioned and 
other clinical randomized trials, several meta-analyses have 
been performed and recently published. Berger et al included 
in their meta-analysis all randomized clinical trials evaluating 
the role of ASA in primary prevention in the years 1966–2005. 
Approximately 95,000 patients were considered. In women,   
a significant 12% reduction in cardiovascular events (RR 
0.88; 95% CI: 0.79–0.99) and a 17% reduction in strokes 
(RR 0.83; 95% CI: 0.70–0.97) was reported for ASA arms in 
these s  tudies. No significant reduction in myocardial infarc-
tion or cardiovascular mortality was detected. In men, ASA 
therapy was associated with a significant 14% reduction in 
cardiovascular events (RR 0.86; 95% CI: 0.78–0.94) and a 
32% reduction in myocardial infarction (RR 0.68; 95% CI: 
0.54–0.86). There was no significant effect on stroke or car-
diovascular mortality.17
De Berardis et al performed a meta-analysis of randomized 
controlled trials to evaluate the effect of low-dose ASA versus 
placebo in people with diabetes and without cardiovascular 
disease. The primary endpoint was major cardiovascular 
events (death from cardiovascular causes, nonfatal myocardial 
infarction, nonfatal stroke, and all-cause mortality). Six studies 
were evaluated, with a total of approximately 10,000 patients. 
Aspirin was not associated with a statistically   significant 
reduction in risk of major cardiovascular events (RR 0.90; 
95% CI: 0.81–1.00), c  ardiovascular mortality (RR 0.94; 
95% CI: 0.72–1.23), or all-cause mortality (RR 0.93; 95% 
CI: 0.82–1.05). However, the risk of myocardial i  nfarction 
was significantly reduced in the ASA arm, but only in males 
(RR 0.57; 95% CI: 0.34–0.94). Overall, bleeding events were 
not increased (RR 2.50; 95% CI: 0.76–8.21).18
As in the previous study, Younis et al evaluated the role 
of ASA for primary prevention in diabetic patients. The 
authors included in their work six randomized clinical trials 
in 7000 patients. Aspirin use did not play a protective role in 
overall mortality (RR 0.96; 95% CI: 0.78–1.18), major cardio-
vascular events (RR 0.90; 95% CI: 0.78–1.05), or myocardial 
infarction (RR 0.95; 95% CI: 0.76–1.18). Also, according to this 
study, bleeding risk was not significantly increased in the ASA 
arm compared with placebo (RR 2.49; 95% CI: 0.70–8.84).19
When including populations with known cardiovascular 
risk factors, such as hypertension, diabetes, or peripheral 
vascular disease, the benefits of antiplatelet therapy are   offset 
by the increase in hemorrhagic risk.20–23 McQuaid and Laine 
performed a systematic review focusing on bleeding risk in 
cardiovascular prophylaxis using ASA. Aspirin increased 
the risk of major bleeding (RR 1.71; 95% 1.41–2.08), major 
gastrointestinal bleeding (RR 2.07; 95% CI: 1.61–2.66), and 
intracranial bleeding (RR 1.65; 95% CI: 1.06–5.99) versus 
placebo. Of the studies included in this review, only one 
reported an increase in gastrointestinal bleeding with ASA 
versus clopidogrel (RR 1.45; 95% CI: 1.00–2.10). However, 
the number needed to treat with clopidogrel versus ASA to 
prevent one gastrointestinal bleeding episode was at least 
800 (at a cost of about one million dollars).24
Based on the aforementioned evidence, the current 
American College of Cardiology/American Heart Associa-
tion guidelines recommend ASA for primary prevention only 
in men with diabetes and intermediate cardiovascular risk, 
and without an increased risk of bleeding.21 On the other 
hand, the European Society of Cardiology guidelines do not 
recommend ASA in primary prevention.25,26
Secondary prevention
Single antiplatelet therapy
In patients with previous peripheral, cerebral, or cardiac 
ischemic events, antiplatelet therapy has clear beneficial 
effects. Major clinical trials testing the effects of single anti-
platelet therapy in secondary prevention are listed in Table 2. 
However, the increased risk of antiplatelet-related   bleeding 
is well known and needs to be kept in mind.
Baigent et al performed a meta-analysis of 16 randomized 
trials evaluating ASA for secondary prevention in approxi-
mately 17,000 patients. The occurrence of serious events 
decreased in the ASA group (6.7% versus 8.2% per year; 
P , 0.0001), with reductions of about 20% in total strokes 
(2.08% versus 2.54% per year; P = 0.002) and in coronary 
events (4.3% versus 5.3% per year; P , 0.0001). These 
results were achieved with a nonsignificant increase in 
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In search of ways to reduce the gastrointestinal side effects 
of ASA, Garcia et al identified over 2000 patients who suffered 
from gastrointestinal bleeding and compared these patients 
with randomly selected controls. The RR of gastrointestinal 
bleeding was 1.9 (95% CI: 1.6–2.3), without significant dif-
ferences between standard and enteric-coated ASA.27,28
Besides ASA, other antiplatelet drugs have been 
proven to be effective in secondary prevention. In CAPRIE 
(  Clopidogrel versus Aspirin in Patients at risk of Ischaemic 
Events), clopidogrel therapy was compared with ASA in a 
randomized manner in 19,000 patients with previous cardio-
vascular events. At the end of two years of follow-up, the 
authors reported a significant risk reduction of the primary 
endpoint (ischemic stroke, myocardial infarction, or vascular 
death) in the clopidogrel group (8.7%; 95% CI: 0.3–16.5) 
compared with ASA, with a similar safety profile between 
the two drugs (any stroke, myocardial infarction, or death 
from any cause being 7.0%; 95% CI: 0.9–14.2).29
Furthermore, several studies evaluating ASA mono-
therapy versus thienopyridines have been performed. In the 
STAMI (Ticlopidine Versus Aspirin After Myocardial Infarc-
tion) trial, ticlopidine was compared with ASA   following 
thrombolysis. The primary endpoint was the composite of 
fatal and nonfatal myocardial infarction, fatal and n  onfatal 
stroke, angina with objective evidence of m  yocardial 
i  schemia, and vascular death. At the end of the study, the pri-
mary endpoint occurred in 8% of patients, without   differences 
between the groups.30
TASS (the Ticlopidine Aspirin Stroke Study) evaluated 
the effects of ticlopidine versus ASA in patients with recent 
ischemic cerebral events. The three-year event rate for non-
fatal stroke or death from any cause was 17% and 19% in the 
ticlopidine and ASA arms, respectively (P = 0.048).31
In the future, newer compounds, including ticagrelor and 
prasugrel, will provide supplementary data on the effectiveness 
of antiplatelet therapy in the secondary prevention setting.32
Double antiplatelet therapy
In high atherothrombotic risk conditions, given the superior 
antithrombotic effect derived from multiple platelet pathway 
inhibition, double antiplatelet therapy has been proposed to   
further reduce cardiovascular events (Table 3).33–35
In the CHARISMA (Clopidogrel for High Athero-
thrombotic Risk and Ischemic Stabilization, Management, 
Table 2 Major clinical trials testing the effects of single antiplatelet therapy in secondary prevention
Aspirin  
dose (mg)
Clopidogrel  
dose (mg)
Ticlopidine 
dose (mg)
Endpoint Conclusions
ATT 50–500 – – CV and hemorrhagic events ischemic event reduction with no 
significant hemorrhagic stroke increase
CAPRie 325  versus 75 – ischemic stroke, Mi, or vascular  
death
Clopidogrel better
STAMi 160 versus  – 500 ischemic stroke, Mi, angina, or vascular 
death
No differences
TASS 1300 versus – 500 Nonfatal stroke or death No differences
Abbreviations: CV, cardiovascular; TASS, Ticlopidine Aspirin Stroke Study; STAMi, Ticlopidine versus Aspirin After Myocardial infarction; CAPRie, Clopidogrel versus 
Aspirin in Patients at risk of ischemic events; Mi, myocardial infarction.
Table 3 Major clinical trials testing the effects of double antiplatelet therapy
Indication Aspirin  
dose (mg)
Clopidogrel  
dose (mg)
Endpoint Conclusions
PLATO Acute coronary  
syndrome
75–325 75 or  
Ticagrelor 10
CV events Fewer ischemic events, similar CV events
CURe Unstable angina  
NSTeMi
75–325 75 CV events Aspirin + clopidogrel better
CReDO Planned PCi 325 75 CV events Aspirin + clopidogrel better
PCi-CLARiTY Fibrinolysis  
after STeMi
75–162 75 CV events Aspirin + clopidogrel better
Helton Meta-analysis of CURe, CReDO,  
CLARiTY, and CHARiSMA
75–325 75 CV events Aspirin + clopidogrel better
MATCH Recent TiA or stroke 75 75 CV events Aspirin alone better
Abbreviations: CV, cardiovascular; TiA, transient ischemic attack; PLATO, A Study of Platelet inhibition and Patient Outcomes; CHARiSMA, Clopidogrel for High 
Atherothrombotic Risk and ischemic Stabilization, Management, and Avoidance; CURe, Clopidogrel in Unstable Angina to Prevent Recurrent events; PCi, percutaneous 
coronary intervention; CLARiTY, Clopidogrel as Adjunctive Reperfusion Therapy; CReDO, Clopidogrel for the Reduction of events During Observation; MATCH, 
Management of ATherothrombosis with Clopidogrel in High-risk patients with recent transient ischemic attack or ischemic stroke; STeMi, ST elevation myocardial infarction; 
NSTeMi, non-ST elevation myocardial infarction.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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and Avoidance) trial, patients with known cardiovascular 
disease or with multiple atherothrombotic risk factors were 
randomized to ASA alone versus ASA plus clopidogrel. 
Although the trial was intended to include a primary preven-
tion population, the presence of diabetes mellitus and/or its 
complications in the vast majority of participants does not 
permit the results to be considered generalizable to a true 
primary prevention context.
The primary endpoint was a composite of vascular death, 
myocardial infarction, or stroke. At the end of the 28-month 
follow-up, the primary endpoint occurred in 6.8% of patients 
on clopidogrel plus ASA versus 7.3% in the placebo plus 
ASA arm (P = 0.22), but the death rate from cardiovascular 
causes was higher in the clopidogrel plus ASA group (3.9% 
versus 2.%; P = 0.01). Death rate for any cause was similar 
between the groups at 0.99 (95% CI: 0.86–1.14).36
The CURE (Clopidogrel in Unstable Angina to Prevent 
Recurrent Events) trial was the first to evaluate double 
antiplatelet therapy following an acute coronary syndrome. 
In this study, over 200 patients with non-ST elevation acute 
coronary syndrome were randomized to pretreatment plus 
long-term therapy with ASA plus clopidogrel versus ASA 
plus placebo. The primary endpoint (the composite of 
  cardiovascular death, myocardial infarction, or urgent t  arget 
vessel revascularization within 30 days of p  ercutaneous 
coronary intervention) occurred less frequently in the active 
treatment group. Long-term clopidogrel plus ASA treatment 
was associated with lower rates of cardiovascular death, 
myocardial infarction, or any revascularization (P = 0.03), 
and of cardiovascular death or myocardial i  nfarction 
(P = 0.047).37
The long-term effectiveness of dual antiplatelet therapy 
was later confirmed by the CREDO (Clopidogrel for the 
Reduction of Events During Observation) trial. In this 
study, over 2000 patients who were candidates for elective 
p  ercutaneous coronary intervention were randomized to ASA 
plus clopidogrel therapy for 12 months versus ASA plus 
clopidogrel for 28 days. From day 29, placebo patients were 
treated with ASA only. The primary endpoint (a   composite of 
death, myocardial infarction, or stroke) at one-year follow-up 
was reduced in the clopidogrel plus ASA group (RR 26.9%; 
P = 0.02). On other hand, the bleeding risk was not signifi-
cantly increased in the clopidogrel plus ASA group (8.8% 
versus 6.7%; P = 0.07).38
In the CLARITY-TIMI (Clopidogrel as   Adjunctive 
  Reperfusion Therapy-Thrombolysis In Myocardial I  nfarction) 
trial, patients with ST segment elevation myocardial infarc-
tion undergoing fibrinolytic treatment were   randomized to 
clopidogrel (including a loading dose) or placebo. The   primary 
outcome (composite of cardiovascular death, recurrent myo-
cardial infarction, or stroke from percutaneous coronary inter-
vention 30 days after randomization) decreased significantly 
in the clopidogrel arm (3.6% versus 6.2%; P = 0.008). The 
clopidogrel group also reported a reduction in myocardial 
infarction and stroke in patients undergoing a percutaneous 
coronary procedure (4.0% versus 6.2%; P = 0.03). These 
results were obtained in the absence of an increase in the risk 
of bleeding in the clopidogrel arm (2.0% versus 1.9% in the 
two groups, respectively; P = 0.99).39
Guided by the extreme need of evidence-based data on this 
topic, a large meta-analysis, including nearly 80,000 patients 
from the major clinical trials, eg, CURE, CREDO, CLARITY, 
CHARISMA, and COMMIT (Clopidogrel and Metoprolol in 
Myocardial Infarction Trial) confirmed a lower incidence of 
all-cause mortality in the ASA plus clopidogrel group compared 
with the ASA alone group (6.3% versus 6.7%; P = 0.026). 
Myocardial infarction occurred in 2.7% of the patients on 
clopidogrel plus ASA compared with 3.3% (P , 0.0001) on 
ASA alone, and occurrence of stroke was 1.2% and 1.4%, 
respectively, in the two groups (P = 0.002). Major bleeding 
was more frequently reported in the double antiplatelet therapy 
group (1.6% versus 1.3%, respectively; P , 0.0001), however 
without a significant difference in terms of fatal bleeding 
(0.28% and 0.27%, respectively; P = 0.79).40
Following the first experience of single antiplatelet 
agents, the new third-generation thienopyridines, i  ncluding 
ticagrelor and prasugrel, have been also suggested for 
combination treatment. The rapid onset of action and lower 
probability of nonresponsiveness accompanied by the 
similar safety profile of prasugrel, for example, compared 
with clopidogrel, represents a promising step forward in 
antiplatelet therapy.41
The TRITON-TIMI (Clopidogrel in Acute Coronary 
Syndrome Subjects Who Are to Undergo   Percutaneous 
  Coronary Intervention-Thrombolysis in Myocardial 
Infarction)38 trial validated the use of prasugrel. This trial 
randomized 13,000 patients with acute coronary syndromes 
and planned coronary percutaneous intervention to receive 
clopidogrel plus ASA versus prasugrel plus ASA. The 
primary endpoint was a composite of cardiovascular death, 
nonfatal myocardial infarction, and nonfatal stroke. The 
primary endpoint occurred in 9.9% patients on prasugrel plus 
ASA versus 12.1% on clopidogrel plus ASA (P , 0.001). 
Furthermore, the occurrence of myocardial infarction was 
significantly reduced in the prasugrel arm (9.7% versus 7.4%; 
P , 0.001). On the other hand, major bleeding occurred in 
1.8% of patients in the clopidogrel plus ASA group versus 
2.4% of those in the prasugrel plus ASA group (P = 0.03). Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Life-threatening bleeding was also significantly increased in 
the prasugrel group (1.4% versus 0.9%; P = 0.01).42
More recently, ticagrelor, a newer antiplatelet agent, has 
been tested in patients with ischemic heart disease. Compared 
with clopidogrel, this reversible antiplatelet drug has shown 
a reduction of cardiovascular death, myocardial infarction, 
and stroke (9% versus 10.7%; P = 0.0025) with no increase 
in major bleeding rates (11.5% versus 11.6%; P = 0.8).43
In addition to the aforementioned experience, double 
antiplatelet therapy has been tested in other clinical settings, 
including transitory ischemic attacks and stroke. In the 
randomized MATCH (Management of Atherothrombosis 
With Clopidogrel in High-Risk Patients) trial, ASA plus 
  clopidogrel was compared with clopidogrel alone in nearly 
8000 high-risk patients with a recent ischemic stroke or 
t  ransient ischemic attack and at least one additional   vascular 
risk factor. The primary endpoint was a composite of 
ischemic stroke, myocardial infarction, vascular death, or 
rehospitalization for acute ischemia. At the end of the study, 
the endpoint occurred in 15.7% in the clopidogrel plus ASA 
arm versus 16.7% in the clopidogrel alone arm (P = 0.24). 
However, life-threatening bleeding episodes were higher in 
the group receiving ASA and clopidogrel versus clopidogrel 
alone (2.6% versus 1.3%; P , 0.001). Based on these results, 
the authors concluded that, in this specific clinical setting, 
adding ASA to clopidogrel is not recommended.44
Fixed-dose antiplatelet 
combinations
Keeping in mind the consequences induced by partial or 
complete suspension of double antiplatelet therapy, patient 
compliance plays a fundamental role. Collet et al designed the 
nationwide REGINA survey to evaluate how the i  nterruption 
of dual oral antiplatelet therapy is managed in “real world” 
practice. Over 2000 physicians were randomly selected 
to participate in a computer-assisted telephone interview. 
Knowledge about drug-eluting stents and dual oral   antiplatelet 
therapy was appraised by multiple-choice q  uestions. Based 
on data from the 93% of the responding practitioners who 
completed the interview, unjustified i  nterruption of dual 
oral antiplatelet therapy was quite frequent (22%). Low-
molecular-weight heparin was the substituted therapy in 
over two-thirds of cases (without available evidence) and 
was associated with longer periods of dual oral antiplatelet 
therapy interruption.45
This evidence highlights the actual problem of therapy 
adherence, and the severe consequences (eg, stent thrombosis 
following percutaneous coronary intervention) related to 
lack of patient compliance with the prescribed treatment. 
Besides the impact on the individual’s health status, lack of 
adherence to medical prescriptions costs about $100 billion 
per year in the US.46
Treatment adherence is defined as “the extent to which 
patients take medications as prescribed by their health care 
providers”. “Compliance” indicates passive patient obedience 
to doctor prescription, and “adherence” involves a major 
comprehension level by the patient. Although poor adher-
ence depends on several factors, including provider–patient 
interaction and drug cost, the number of administrations per 
day, is indeed a non-negligible element.47–51
In this context, in patients for whom double antiplatelet 
therapy has proven indications, fixed-dose formulations have 
a promising role. In patients at high cardiovascular risk, who 
are often on multiple drug treatment, combining adminis-
tration of two antiplatelet agents in a single pill, thereby 
reducing the number of administrations per day represents an 
excellent option to improve treatment adherence.52,53
The first fixed-dose combination available was Aggrenox® 
(Boehringer Ingelheim, Ingelheim am Rhein, Germany) 
containing ASA 25 mg and extended-release dipyridamole 
200 mg. Serebruany et al evaluated the results of a combina-
tion of extended-release dipyridamole (ER-DP) and low-dose 
ASA compared with clopidogrel with or without ASA in 
diabetic patients. The study enrolled 60 patients aged over 
40 years, with a diagnosis of type 2 diabetes and a history 
of transient ischemic attacks. Patients were allocated to 
receive ER-DP + ASA 200/25 mg twice daily, clopidogrel 
75 mg/day, or a daily combination of clopidogrel 75 mg 
and ASA 81 mg.53 The primary endpoint was the change in 
platelet receptor expression at 30-day follow-up. ER-DP and 
ASA therapy was associated with a significant reduction in 
the glycoprotein IIb/IIIa receptor, clopidogrel monotherapy 
was associated with ADP-induced platelet aggregation, and 
the ASA and clopidogrel combination was associated with 
inhibition of collagen-induced platelet aggregation. These 
interesting data indeed clarified the molecular action of the 
best known antiplatelet therapy, but did not add information 
concerning clinical outcomes.54,55
Knowledge regarding the association between clopidogrel 
and ASA is to date elementary. From a pharmacokinetic 
point of view, clopidogrel is rapidly absorbed, reaching peak 
plasma levels at approximately one hour following dosing. 
However, the active formulation is formed by oxidation 
to 2-oxo-clopidogrel and subsequent hydrolysis, regulated 
primarily by cytochrome P450. The active metabolite binds 
irreversibly to platelet receptors. Clopidogrel metabolites are Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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then excreted 50% in the urine and 50% in the feces, with 
a half-life for the main circulating metabolite of about eight 
hours. On the other hand, ASA is rapidly hydrolyzed in plasma 
to salicylic acid, with a half-life of 20 minutes, and peak sali-
cylic acid concentrations occur one hour after administration. 
Salicylic acid is then conjugated primarily in the liver to form 
salicyluric acid. The half-life of these molecules is about two 
hours and metabolites are excreted in the urine.
Based on these presumptions, two fixed-dose combination 
tablets containing ASA and clopidogrel have recently been 
formulated, ie, DuoPlavin®/DuoCover®, a clopidogrel 75 mg 
and acetylsalicylic acid 100 mg or 75 mg combination (sanofi-
aventis, Paris, France; Bristol-Myers Squibb, New York, NY) 
and CLOPIVAS-AP®, a fixed-dose combination of clopidogrel 
75 mg and ASA 75 mg or 100 mg (Cipla, Mumbai, India).
To date, these formulations are under careful investigation, 
and the European Medicines Agency has recently requested 
scientific data concerning bioequivalence and pharmacokinetics 
before allowing full product marketing. In the event of f  avorable 
results, a single tablet with two fixed-dose antiplatelet drugs 
may be used in a wide spectrum of patients moving towards 
superior patient adherence, relevant especially in high-risk 
cardiovascular patients (eg, following coronary intervention), 
without an increase in side effects or bleeding risk.
Conclusion
Antiplatelet therapy plays a fundamental role in reducing 
atherothrombotic events in patients at risk via several path-
ways. The possibility of reversible or irreversible modulation 
of platelet activation represents one of most important con-
temporary medical challenges. When fixed-dose formulation 
tablets become available, adherence with double platelet 
therapy may increase, with substantial benefits not only for 
patients, but also for public health expenditure.
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